Page last updated: 2024-10-17

aminocaproic acid and Hermanski-Pudlak Syndrome

aminocaproic acid has been researched along with Hermanski-Pudlak Syndrome in 1 studies

Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.

Hermanski-Pudlak Syndrome: Syndrome characterized by the triad of oculocutaneous albinism (ALBINISM, OCULOCUTANEOUS); PLATELET STORAGE POOL DEFICIENCY; and lysosomal accumulation of ceroid lipofuscin.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Merideth, MA1
Introne, WJ1
Wang, JA1
O'Brien, KJ1
Huizing, M1
Gochuico, BR1

Other Studies

1 other study available for aminocaproic acid and Hermanski-Pudlak Syndrome

ArticleYear
Genetic variants associated with Hermansky-Pudlak syndrome.
    Platelets, 2020, May-18, Volume: 31, Issue:4

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Platelets; Carrier Proteins; Contusions; Deamino A

2020